- Shanghai Nianxing Industrial Co., Ltd
- China
- Product Name: doxycycline hydrochloride
- Price:
- Purity: 98.0%
- Stocking Period: 10 Day
- Contact: Yang
- Shanghai Jizhi Biochemical Technology Co., Ltd
- China
- Product Name: doxycycline hydrochloride
- Price: ￥1418.0/25g ￥288.0/5g
- Purity: 98.0%
- Stocking Period: 1 Day
- Contact: Liu jia
- ShangHai DC Chemicals Co.,Ltd
- China
- Product Name: Doxycycline Hydrochloride
- Price: ￥Inquiry/1g
- Purity: 98.9%
- Stocking Period: 1 Day
- Contact: Tony Lai
- DC Chemicals Limited
- China
- Product Name: Doxycycline Hydrochloride
- Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/500mg
- Purity: 98.0%
- Stocking Period: 3 Day
- Contact: Tony Cao
- Dayang Chem (Hangzhou) Co., Ltd.
- China
- Product Name: Doxycycline hydrochloride
- Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
- Purity: 98.0%
- Stocking Period: Inquiry
- Contact: Ms Wang
10592-13-9
10592-13-9 structure
- Name: doxycycline hydrochloride
- Chemical Name: doxycycline HCl
- CAS Number: 10592-13-9
- Molecular Formula: C22H25ClN2O8
- Molecular Weight: 480.896
- Catalog: Biochemical Inhibitor Proteases MMP inhibitor
- Create Date: 2018-02-05 08:00:00
- Modify Date: 2024-01-02 16:31:05
-
Doxycycline hydrochloride is a tetracycline antibiotic and broad-spectrum metalloproteinase (MMP) inhibitor.
| Name | doxycycline HCl |
|---|---|
| Synonyms |
Doxylin
samecin (4S,4aR,5S,5aR,6R,12aS)-4-(Dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide hydrochloride (1:1) (4S,4aR,5S,5aR,6R,12aS)-4-(Dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-2-tetracenecarboxamide hydrochloride liomycin EINECS 234-198-7 (4S,4aR,5S,5aR,6R,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide Monohydrochloride Doxycycline (hydrochloride) Doxycycline HCl tecacin DOXYCYCLINE doxycycline hyclate doxycycline hydrochloride ecodox MFCD03427564 6-deoxy-5-oxytetracycline hydrochloride novadox retens DOXYCYCLINEHCL HYDRAMYCIN doxy-ii a-6-Deoxy-5-hydroxytetracycline Hydrochloride mespafin 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)-, hydrochloride (1:1) (4S,4aR,5S,5aR,6R,12aS)-4-(Dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-2-tetracenecarboxamide hydrochloride (1:1) (4S-(4a,4aa,5a,5aa,6a,12aa))-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide Monohydrochloride midoxin |
| Description | Doxycycline hydrochloride is a tetracycline antibiotic and broad-spectrum metalloproteinase (MMP) inhibitor. |
|---|---|
| Related Catalog | |
| Target |
MMP |
| In Vitro | Doxycycline shows excellent effectiveness and time-dependent characteristics against M. gallisepticum strain S6 in vitro[2]. Osteoblasts exposed to the composite containing 25 μg/mL doxycycline (DOX)/β-cyclodextrin (βCD) has increased cell proliferation (p < 0.05) compared to control osteoblast cultures at all experimental time points, reaching a maximum in the second week. Alkaline phosphatase (AP) activity and collagen secretion levels are also elevated in osteoblasts exposed to the DOX/βCD composite (p < 0.05 vs. controls) and reach a maximum after 14 days[3]. Doxycycline (20 nM) inhibits ECM (extracellular matrix) production and remodeling in both SMC (smooth muscle cell) types of cultures, and synthesis of collagens and isoprenylated proteins in SMC-Ch (a cholesterol-rich diet) is a higher than in SMC-C (a standard diet)[4]. |
| In Vivo | In heterozygous (HT) Col3a1 knockout mice, after 3 months of treatment with doxycycline or placebo, 9-month-old HT or wild-type (WT) mice are subjected to surgical stressing of the aorta. A 3-fold increase in stress-induced aortic lesions found in untreated HT mice 1 week after intervention (cumulative score 4.5±0.87 versus 1.3±0.34 in WT, p<0.001) is fully prevented in the doxycycline (25 or 100 mg/kg, p.o.)-treated group (1.1±0.56)[1]. |
| Kinase Assay | Gelatin (0.1% (w/v) is added to standard LaemmLi acrylamide polymerization mixture. Tissue extract is mixed 1:2 with sample buffer [250 mM Tris-Cl pH 6.8, 10% (w/v) SDS, 20% (v/v) glycerol, 0.005% (w/v) bromphenol blue]. Serum is diluted 1:10 with electrophoresis buffer (2.5 mM Tris, 20 mM glycine, 0.005% SDS) and mixed 1:2 with sample buffer. Twenty μLs are loaded after 10-min incubation at room temperature without boiling. After electrophoresis at 90 V, the gels are soaked in 2.5% (w/v) Triton X-100, incubated 2 to 3 days at 37°C in gelatin digestion buffer [50 mM Tris-Cl, pH 8.0, 8 mM CaCl2, 10 mM ZnSO2, 0.02% (w/v) NaN3], stained in 0.05% Coomassie blue R-250 in acetic acid/methanol/water (1:4.5:4.5 by volume), destained in 10% acetic acid and 5% methanol, and scanned for lysis band intensity. The lysis band intensity is proportional to gelatinase activity and is quantified densitometrically by using One-Dimensional Scan software. The result, a number between 0.07 and 3.75, is normalized to the protein content by dividing the densitometry result with the relative optical density from the BCA protein assay kit result. The result is used for the analysis as the arbitrary unit. For the total MMP activity results of lysis bands of pro-MMP-9, active MMP-9, pro-MMP-2, and active MMP-2 are added. A protein size marker is used to determine the correct size. |
| Cell Assay | All in vitro treatments are performed in SMC cultures at 90% confluence, when ECM synthesis in SMC starts to be evident. Doxycycline (20 nM) is diluted in culture medium at a concentration of 10 μg/mL (20 nM), at which no toxicity or variation in primary cultured SMC proliferation has been reported, as well as in other cell lines and the incubation time is 48 h. SMC-C and SMC-Ch are seeded at equal cell density in 6-well plates and, when confluence reaches 90%, 1 mL culture medium is added to each well containing 3.7×104 Bq L-[5-H3]-proline (9.62×1011 Bq/mmol). After 48 h incubation, cells are lysed with 0.5 mL 0.5 mol/L NaOH for 1 h. The resulting solution is neutralized with an equal amount of 0.5 mol/L HCl, and 50 μL are used to measure total proteins with the Bradford method. One volume of 10% TCA is added to the remaining 250 μL and centrifuged at 13,000 g for 15 min at 4°C. The resulting precipitate is dissolved in 100 μL 0.2 mol/L NaOH, and then neutralized with 1 mol/L HCl. The solution is incubated with collagenase buffer (Tris-HCl, pH 7.6 20 mM, and CaCl2 250 mM final concentration) and 10 units of collagenase at 37°C overnight. Then, 150 μL 10% TCA are added and centrifuged at 13000 g for 15 min at 4°C. The resulting supernatant is added to 4 mL of scintillation fluid and the radioactivity is measured in a liquid scintillation counter LS 600 TA. |
| Animal Admin | Two groups of 6-month-old female heterozygous (HT) Col3a1 knockout mice are treated for 3 months with doxycycline. Treatment is provided with food containing 200 or 800 mg/kg of doxycycline. Because preliminary measured food intake of these mice is averaged at 3.5 g/day and the average body weight of animals is 25 g, the average drug dose for low- and high-dose groups is 25 (Doxy25) or 100 (Doxy100) mg/kg per day, respectively. Untreated (wild type) WT and HT mice are maintained on a regular diet (NIH-07 mouse/rat diet) and served as controls. After 3 months, under general inhalation anesthesia (2% of isoflurane in oxygen) and aseptic conditions, the abdominal aortas are surgically exposed and stressed by the following technique: the blood flow is stopped by occluding the abdominal aorta against the spinal column with a sterile cotton-tip applicator pressed at the level of the renal arteries. After 30 s a second applicator is pressed at the level of iliac bifurcation and the first applicator is abruptly released, followed by release of the second applicator. The abdominal incision is sutured closed, and mice are returned to home cages. The treatment is continued after the intervention. One week after intervention mice are euthanized by an overdose of isoflurane. Blood is collected, and aortas and segments of colon and skin are harvested. |
| References |
| Density | 1.63 g/cm3 |
|---|---|
| Boiling Point | 762.6ºC at 760 mmHg |
| Melting Point | 195-201℃ |
| Molecular Formula | C22H25ClN2O8 |
| Molecular Weight | 480.896 |
| Flash Point | 415ºC |
| Exact Mass | 480.129944 |
| PSA | 181.62000 |
| LogP | 1.15470 |
| Storage condition | 0-6°C |
| Water Solubility | H2O: 50 mg/mL, clear, yellow-green |
Synonym:Biocamycin; Doxigalumicina; Doxycycline Hyclate; Doxy-II; Midoxin; Novadox; Retens; Tetradox; Vibradox; Hydramycin Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
Risk Phrases: None Listed. Section 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW
Not available. Potential Health Effects Eye: May cause eye irritation. Skin: May cause skin irritation. Ingestion: May cause irritation of the digestive tract. May cause liver damage. May cause bone structure abnormalities. May be harmful if swallowed. May produce nervous system disturbances. Inhalation: May cause respiratory tract irritation. May cause effects similar to those described for ingestion. Chronic: May cause liver and kidney damage. May cause bone marrow abnormalities with damage to blood forming tissues. Adverse reproductive effects have been reported in animals. Section 4 - FIRST AID MEASURES Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid. Skin: Get medical aid. Wash clothing before reuse. Flush skin with plenty of soap and water. Ingestion: Do not induce vomiting. If victim is conscious and alert, give 2-4 cupfuls of milk or water. Never give anything by mouth to an unconscious person. Get medical aid. Inhalation: Remove from exposure and move to fresh air immediately. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation. If breathing has ceased apply artificial respiration using oxygen and a suitable mechanical device such as a bag and a mask. Notes to Physician: Treat symptomatically and supportively. Section 5 - FIRE FIGHTING MEASURES General Information: As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Extinguishing Media: Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam. Section 6 - ACCIDENTAL RELEASE MEASURES General Information: Use proper personal protective equipment as indicated in Section 8. Spills/Leaks: Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions. Provide ventilation. Section 7 - HANDLING and STORAGE Handling: Wash thoroughly after handling. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Storage: Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Keep refrigerated. (Store below 4C/39F.) Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION Engineering Controls: Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 10592-13-9: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166. Skin: Wear appropriate protective gloves to prevent skin exposure. Clothing: Wear appropriate protective clothing to prevent skin exposure. Respirators: Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced. Section 9 - PHYSICAL AND CHEMICAL PROPERTIES Physical State: Powder Color: yellow Odor: Not available. pH: Not available. Vapor Pressure: Not available. Viscosity: Not available. Boiling Point: Not available. Freezing/Melting Point: Not available. Autoignition Temperature: Not applicable. Flash Point: Not applicable. Explosion Limits, lower: Not available. Explosion Limits, upper: Not available. Decomposition Temperature: Solubility in water: Specific Gravity/Density: Molecular Formula: C22H24N2O8HCl Molecular Weight: 480.6366 Section 10 - STABILITY AND REACTIVITY Chemical Stability: Stable. Conditions to Avoid: Incompatible materials, dust generation, excess heat, strong oxidants. Incompatibilities with Other Materials: Oxidizing agents. Hazardous Decomposition Products: Hydrogen chloride, nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide. Hazardous Polymerization: Has not been reported Section 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 10592-13-9: QI8925000 LD50/LC50: CAS# 10592-13-9: Oral, mouse: LD50 = 1890 mg/kg; Oral, rat: LD50 = 1700 mg/kg. Carcinogenicity: Doxycycline Hydrochloride - Not listed by ACGIH, IARC, or NTP. Other: See actual entry in RTECS for complete information. Section 12 - ECOLOGICAL INFORMATION Section 13 - DISPOSAL CONSIDERATIONS Products which are considered hazardous for supply are classified as Special Waste and the disposal of such chemicals is covered by regulations which may vary according to location. Contact a specialist disposal company or the local waste regulator for advice. Empty containers must be decontaminated before returning for recycling. Section 14 - TRANSPORT INFORMATION IATA No information available. IMO No information available. RID/ADR No information available. Section 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives Hazard Symbols: XN Risk Phrases: Safety Phrases: S 28A After contact with skin, wash immediately with plenty of water. S 37 Wear suitable gloves. S 45 In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). WGK (Water Danger/Protection) CAS# 10592-13-9: 2 Canada CAS# 10592-13-9 is listed on Canada's DSL List. CAS# 10592-13-9 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 10592-13-9 is not listed on the TSCA inventory. It is for research and development use only. SECTION 16 - ADDITIONAL INFORMATION N/A |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Hazard Codes | Xn: Harmful;Xi: Irritant; |
|---|---|
| Risk Phrases | R22 |
| Safety Phrases | 26-36/37 |
| WGK Germany | 3 |
| HS Code | 29413000 |
|
~92%
10592-13-9 |
| Literature: WO2005/112945 A2, ; Page/Page column 117-118 ; |
| HS Code | 29413000 |
|---|